Aspira Women’s Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aspira Women's Health Inc.

AUSTIN, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25^th Annual Global Investment Conference, which is scheduled to take place on September 11-13, 2023 in New York, NY. Management will also be available for one-on-one meetings. Details are as follows:

H.C. Wainwright 25^th Annual Global Investment Conference
Date: Monday, September 11, 2023
Time: webcast available starting at 7:00 am ET
Location: New York, NY and virtual
Registration Link: Click HERE

The webcast will also be available for viewing and replay on the Investor Relations portion of the Company’s website.

About Aspira Women’s Health Inc. 
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM, which includes OvaWatch^SM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus^® combines our FDA-cleared products, Ova1^® and Overa^®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck^SM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Monique Kosse 
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820
monique@lifesciadvisors.com